Biotie Successfully Completes Imaging Study with SYN120
The PET study was conducted at the Johns Hopkins University School of Medicine in the United States. It evaluated occupancy of the 5-HT6 receptor in the brain in nine healthy volunteers who were treated with different doses of SYN120. The results demonstrate that target levels of receptor occupancy expected for efficacy can be achieved with SYN120 doses that are an order of magnitude lower than those that have previously been shown to be safe and well tolerated for up to two weeks in healthy older volunteers.
"We are extremely pleased with the outcome of this study," commented Dr Timo Veromaa, Biotie's Chief Executive Officer. "These data suggest that Phase 2 trials can be conducted at doses that are fully expected to be therapeutic and yet maintain a wide safety margin. We are now in the process of preparing a Phase 2 enabling package to be submitted to Roche for their evaluation."